GlassScriptPhysician profile
Thomas W Mcculloh
NPI 1407879661
$3,435.89
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2020: $288 · 2021: $1,033 · 2022: $712 · 2023: $709 · 2024: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $964.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $680.01 | 2020-2024 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $536.36 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $431.09 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Sanofi-Aventis U.S. LLC | $364.22 | 2019-2023 | |
| Amgen INC. | $261.99 | 2021-2024 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $218.97 | 2019-2024 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $138.21 | 2019-2023 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $86.94 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $84.61 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.27 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $73.16 | 2019 | |
| Janssen Pharmaceuticals, INC | $63.74 | 2019-2021 | |
| Lilly USA, LLC | $59.62 | 2021-2024 | Mounjaro, Zepbound |
| Teva Pharmaceuticals USA, INC. | $57.36 | 2020-2023 | Austedo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.46 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $44.84 | 2019-2020 | |
| Biogen, INC. | $42.95 | 2021 | |
| Pfizer INC. | $40.95 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $21.08 | 2021 | |
| Axsome Therapeutics, INC. | $19.48 | 2022 | |
| Phathom Pharmaceuticals, INC. | $17.49 | 2024 | Voquezna |
| Genentech USA, INC. | $16.80 | 2019 | |
| Hologic Sales and Service, LLC | $14.53 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.18 | 2022 | |
| Allergan, INC. | $12.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mcculloh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.